ERBB2 and breast cancer: In this trial, the addition of OFS to tamoxifen appeared particularly effective in patients with HER2+ BC (DFS hazard ratio, 0.41; 95% CI 0.22–0.75) compared with those with HER2− BC (0.83; 95% CI 0.67–1.04) [112].